WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H319928
CAS#: 54-96-6 (free base)
Description: Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The phosphate salt of amifampridine is a more stable formulation that does not require refrigeration. In the United States, amifampridine is under investigation for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Amifampridine is also used to treat many of the congenital myasthenic syndromes, particularly those with defects in choline acetyltransferase, downstream kinase 7, and those where any kind of defect causes "fast channel" behaviour of the acetylcholine receptor.
Hodoodo Cat#: H319928
Name: Amifampridine
CAS#: 54-96-6 (free base)
Chemical Formula: C5H7N3
Exact Mass: 109.06
Molecular Weight: 109.132
Elemental Analysis: C, 55.03; H, 6.47; N, 38.50
Related CAS #: 54-96-6 (free base) 446254-47-3 (phosphate)
Synonym: 3,6-DAP; BRN-0110232; BRN 0110232; BRN0110232; NSC 521760; SC10; Amifampridine; Firdapse.
IUPAC/Chemical Name: 3,4-Diaminopyridine
InChi Key: OYTKINVCDFNREN-UHFFFAOYSA-N
InChi Code: InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
SMILES Code: NC1=C(N)C=NC=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related: 54-96-6 (Amifampridine free base) 446254-47-3 (Amifampridine phosphate).
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 109.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, Brannagan T, Lavrnić D, Shieh P, Vial C, Meisel A, Komoly S, Schoser B, Sivakumar K, So Y; LEMS Study Group. Amifampridine phosphate (Firdapse®) is Effective and Safe in A Phase 3 Clinical Trial in LEMS. Muscle Nerve. 2016 Feb 6. doi: 10.1002/mus.25070. [Epub ahead of print] PubMed PMID: 26852139.
2: Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M. The European LEMS Registry: Baseline Demographics and Treatment Approaches. Neurol Ther. 2015 Dec;4(2):105-24. doi: 10.1007/s40120-015-0034-0. Epub 2015 Nov 2. PubMed PMID: 26525537; PubMed Central PMCID: PMC4685864.
3: Haroldsen PE, Musson DG, Hanson B, Quartel A, O'Neill CA. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults. Clin Ther. 2015 Jul 1;37(7):1555-63. doi: 10.1016/j.clinthera.2015.05.498. Epub 2015 Jun 20. PubMed PMID: 26101174.
4: Haroldsen PE, Garovoy MR, Musson DG, Zhou H, Tsuruda L, Hanson B, O'Neill CA. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099. doi: 10.1002/prp2.99. Epub 2014 Dec 9. PubMed PMID: 25692017; PubMed Central PMCID: PMC4317230.
5: Dooms M, Pincé H, Simoens S. Do we need authorized orphan drugs when compounded medications are available? J Clin Pharm Ther. 2013 Feb;38(1):1-2. doi: 10.1111/jcpt.12006. Epub 2012 Sep 14. PubMed PMID: 22973866.
6: Sedehizadeh S, Keogh M, Maddison P. The use of aminopyridines in neurological disorders. Clin Neuropharmacol. 2012 Jul-Aug;35(4):191-200. doi: 10.1097/WNF.0b013e31825a68c5. Review. PubMed PMID: 22805230.
7: Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341-9. doi: 10.2147/NDT.S10464. Epub 2011 May 30. PubMed PMID: 21822385; PubMed Central PMCID: PMC3148925.
8: Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther. 2012 Feb;37(1):53-7. doi: 10.1111/j.1365-2710.2011.01249.x. Epub 2011 Apr 19. PubMed PMID: 21501202.